Compare PESI & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | IMRX |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.8M | 232.9M |
| IPO Year | 1992 | 2021 |
| Metric | PESI | IMRX |
|---|---|---|
| Price | $13.90 | $6.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 175.0K | ★ 1.1M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,661,000.00 | N/A |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $82.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.25 | $1.10 |
| 52 Week High | $16.50 | $10.08 |
| Indicator | PESI | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 43.00 |
| Support Level | $12.02 | $6.42 |
| Resistance Level | $12.75 | $6.81 |
| Average True Range (ATR) | 0.65 | 0.47 |
| MACD | 0.15 | -0.10 |
| Stochastic Oscillator | 91.28 | 9.07 |
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.